KING OF PRUSSIA, Pa. — Oct. 24, 2016 — Genomind®, a personalized medicine company that provides genetic testing services to help guide better treatments for patients with mental illness, continues to receive awards and recognition for its successes.
The Philadelphia 100® Awards has named Genomind to its list of the 100 fastest growing companies in the region after a review of company data. The Philadelphia 100 is organized by the Wharton Small Business Development Center and The Entrepreneurs’ Forum of Greater Philadelphia.
In addition, Lehigh Valley Business has announced Genomind is a finalist for Business of the Year (in the category of 25–100 employees). The awards program “celebrates the region’s most dynamic businesses and business leaders who share a commitment to professional excellence, business growth and the community,” according to officials.
“These honors speak to the vision of our company plan and expert execution of it, the quality of our employees, and the value we place on making a difference in patients’ lives who rely on our services. I think it’s also important to note that the entire region is a springboard for biotechnology and we are fortunate to base our headquarters and lab here. We look forward to even more advancements for our company and the region in the years ahead,” says Michael Koffler, President and Chief Executive Officer, Genomind.
Earlier this year the company was a finalist for the Patient Impact Award from Pennsylvania Bio, the statewide trade association representing Pennsylvania’s life sciences industry. Genomind was also named one of the best places to work in healthcare in 2016 by Modern Healthcare magazine.
About Genomind
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com
